LEBLAUF Webside schaefer - Kliniken Essen-Mitte

57. Schäfer M, Georg W, Mühlinghaus I, Froehmel A, Rolle D, Pelz J, Heinz A, Burger W.
Neue Lehr- und Prüfungsformen im Fach Psychiatrie. Erfahrungen mit einem reformierten
Curriculum. Nervenarzt 2007; 78:283-293 IF: 0.711
58. Friebe A, Schwarz MJ, Schmidt-Wendtner M, Volkenandt M, Schmidt F, Horn M,
Janssen G, Schaefer M. Pre-treatment levels of sTNF-R1 and sIL-6R are associated with a
higher vulnerability for IFN-alpha induced depressive symptoms in patients with
malignant melanoma. Journal of Immunotherapy 2007; 30: 333-337 IF: 4.837
59. Schäfer M. Ambulanter Alkoholentzug – Neue Trends in der Pharmakotherapie. Der
Neurologe & Psychiater (DNP) 2007; 7:37-40
60. Schäfer M. Depressionen bei Patienten mit Tumorerkrankungen. Der Onkologe 2007;
7(13): 632-641
61. Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, Sarkar R,
Friebe A, Heinz A, Kluschke M, Ziemer M, Gutsche J, Weich V, Halangk J, Berg T:
Hepatitis C treatment in psychiatric “difficult to treat patients” with pegylated interferonalfa
and ribavirin: response and psychiatric side effects. Hepatology 2007; 46:991-998
IF: 10.734
62. Schaefer M, Leopold K, Hinzpeter A, Heinz A, Krebs M. Memantine associated reversal
of clozapine induced weight gain. Pharmacopsychiatry 2007; 40:149-151 IF: 2.849
63. Schäfer M. Depressionen bei Tumorpatienten. Best Practice – Onkologie 2007; 6(2): 50-
59
64. Forsthoff A, Grunze H, Seemüller F, Stampfer R, Dittmann S, Amann B, Schmidt F,
Schäfer M, Hermlec L, Walden J, Schreiner A. Risperidone monotherapy in manic
inpatients- an open label, multicenter trial. World Journal of Biological Psychiatry 2007;
8(4):256-61 IF: 1.698
65. Wittchen HU, Apelt SM, Soyka M, Gastpar M, Backmund M, Gölz J, Kraus MR, Tretter
F, Schäfer M, Siegert J, Scherbaum N, Rehm J, Bühringer G. One Year Retention and
Outcomes of Methadone and Buprenorphine Maintenance Treatments in Routine Care: A
Nationwide Study of 2694 Patients with Opioid Dependence. Drug and Alcohol
Dependence 2008; 5:245-257 (2008) Mar 10 [Epub ahead of print] IF: 3.222
66. Schaefer M. and Mauss S. Clinical management of Interferon-alpha-associated psychiatric
side effects during hepatitis C treatment in patients with drug addiction. Current Drug
Abuse Reviews 2008; 1:177-187
67. Schaefer M, Winterer J, Sarkar R, Uebelhack R, Franke L, Heinz A, Friebe A. Three cases
of successful tryptophan add-on or monotherapy of Hepatitis C and IFN-alpha associated
depression. Psychosomatics 2008; 49(5):442-6. IF: 2.199
68. Hauschild A, Kähler KC, Schäfer M, Fluck M. Interdisciplinary management
recommendations for toxicity associated with interferon-alfa therapy. J Dtsch Dermatol
Ges. 2008 6(10):829-837. Epub 2008 Mar 26. IF: 0.8
12